<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117339">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575483</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-171</org_study_id>
    <nct_id>NCT01575483</nct_id>
  </id_info>
  <brief_title>Korean Post-marketing Surveillance for Onglyza®</brief_title>
  <official_title>Korean Post-marketing Surveillance for Onglyza®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing surveillance is to investigate and confirm the type and
      incidence of newly identified adverse events and any other factors affecting safety and
      efficacy of Onglyza® so that the regulatory authority can manage the marketing approval
      properly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events and Serious Adverse Events</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Onglyza® measured by Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2-hr post-prandial glucose (2-hr PPG) comparing baseline data</measure>
    <time_frame>Baseline (Week 0), 12 weeks and 24 weeks of registration</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3433</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with T2DM</arm_group_label>
    <description>Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Intervention (subjects were previously treated with Onglyza®)</intervention_name>
    <description>No Intervention</description>
    <arm_group_label>Patients with T2DM</arm_group_label>
    <other_name>saxagliptin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of type 2 diabetes mellitus initiating Onglyza® treatment within
        the approved indications will be enrolled
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients who are at least 18 years of age

          -  Patients with diagnosis of T2DM initiating Onglyza® treatment within the approved
             indications in Korea

        Exclusion Criteria:

          -  Indication which is not approved for Onglyza® in Korea

          -  Patients with contraindication for the use of Onglyza® (as clarified in Korean label)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 22, 2016</lastchanged_date>
  <firstreceived_date>April 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
